#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=There is little published literature considering the role of palliative radiotherapy in metastatic sarcoma , although it is recommended as a treatment option for palliation by both the UK bone and soft tissue sarcoma guidelines and the European Society of Medical Oncology ( ESMO ) guidelines .
3-1	15-20	There	_	_	_	_
3-2	21-23	is	_	_	_	_
3-3	24-30	little	abstract[3]	new[3]	_	_
3-4	31-40	published	abstract[3]	new[3]	_	_
3-5	41-51	literature	abstract[3]	new[3]	_	_
3-6	52-63	considering	_	_	_	_
3-7	64-67	the	abstract[4]	new[4]	coref	8-16[46_4]
3-8	68-72	role	abstract[4]	new[4]	_	_
3-9	73-75	of	abstract[4]	new[4]	_	_
3-10	76-86	palliative	abstract[4]|abstract[5]	new[4]|new[5]	ana	3-17[0_5]
3-11	87-99	radiotherapy	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-12	100-102	in	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-13	103-113	metastatic	abstract[4]|abstract[5]|abstract[6]	new[4]|new[5]|new[6]	coref	3-34[0_6]
3-14	114-121	sarcoma	abstract[4]|abstract[5]|abstract[6]	new[4]|new[5]|new[6]	_	_
3-15	122-123	,	_	_	_	_
3-16	124-132	although	_	_	_	_
3-17	133-135	it	abstract	giv	coref	4-19[25_0]
3-18	136-138	is	_	_	_	_
3-19	139-150	recommended	_	_	_	_
3-20	151-153	as	_	_	_	_
3-21	154-155	a	_	_	_	_
3-22	156-165	treatment	event	new	_	_
3-23	166-172	option	_	_	_	_
3-24	173-176	for	_	_	_	_
3-25	177-187	palliation	abstract	new	coref	8-19[47_0]
3-26	188-190	by	_	_	_	_
3-27	191-195	both	object[11]	new[11]	coref	10-5[0_11]
3-28	196-199	the	object[11]	new[11]	_	_
3-29	200-202	UK	place|object[11]	new|new[11]	_	_
3-30	203-207	bone	object[11]	new[11]	_	_
3-31	208-211	and	_	_	_	_
3-32	212-216	soft	event[14]	new[14]	coref	3-46[0_14]
3-33	217-223	tissue	object|event[14]	new|new[14]	coref	10-1[56_0]
3-34	224-231	sarcoma	abstract|event[14]	giv|new[14]	coref	4-22
3-35	232-242	guidelines	event[14]	new[14]	_	_
3-36	243-246	and	_	_	_	_
3-37	247-250	the	organization[15]	new[15]	_	_
3-38	251-259	European	organization[15]	new[15]	_	_
3-39	260-267	Society	organization[15]	new[15]	_	_
3-40	268-270	of	organization[15]	new[15]	_	_
3-41	271-278	Medical	organization[15]|abstract[16]	new[15]|new[16]	appos	3-44[0_16]
3-42	279-287	Oncology	organization[15]|abstract[16]	new[15]|new[16]	_	_
3-43	288-289	(	organization[15]	new[15]	_	_
3-44	290-294	ESMO	organization[15]|abstract	new[15]|giv	_	_
3-45	295-296	)	organization[15]	new[15]	_	_
3-46	297-307	guidelines	organization[15]|event	new[15]|giv	ana	4-6
3-47	308-309	.	_	_	_	_

#Text=To the authors ’ knowledge this is the largest retrospective study published to date reviewing the use of palliative radiotherapy for sarcoma .
4-1	310-312	To	_	_	_	_
4-2	313-316	the	abstract[20]	new[20]	_	_
4-3	317-324	authors	person[19]|abstract[20]	new[19]|new[20]	_	_
4-4	325-326	’	person[19]|abstract[20]	new[19]|new[20]	_	_
4-5	327-336	knowledge	abstract[20]	new[20]	_	_
4-6	337-341	this	event	giv	coref	4-8[22_0]
4-7	342-344	is	_	_	_	_
4-8	345-348	the	event[22]	giv[22]	coref	6-1[32_22]
4-9	349-356	largest	event[22]	giv[22]	_	_
4-10	357-370	retrospective	event[22]	giv[22]	_	_
4-11	371-376	study	event[22]	giv[22]	_	_
4-12	377-386	published	_	_	_	_
4-13	387-389	to	_	_	_	_
4-14	390-394	date	time	new	_	_
4-15	395-404	reviewing	_	_	_	_
4-16	405-408	the	abstract[24]	new[24]	_	_
4-17	409-412	use	abstract[24]	new[24]	_	_
4-18	413-415	of	abstract[24]	new[24]	_	_
4-19	416-426	palliative	abstract[24]|abstract[25]	new[24]|giv[25]	coref	5-5[28_25]
4-20	427-439	radiotherapy	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
4-21	440-443	for	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
4-22	444-451	sarcoma	abstract[24]|abstract[25]|abstract	new[24]|giv[25]|giv	coref	5-15[31_0]
4-23	452-453	.	_	_	_	_

#Text=The results confirm that palliative radiotherapy can successfully provide symptomatic benefit to patients with metastatic sarcoma .
5-1	454-457	The	abstract[27]	new[27]	coref	7-23[42_27]
5-2	458-465	results	abstract[27]	new[27]	_	_
5-3	466-473	confirm	_	_	_	_
5-4	474-478	that	_	_	_	_
5-5	479-489	palliative	abstract[28]	giv[28]	coref	8-13[0_28]
5-6	490-502	radiotherapy	abstract[28]	giv[28]	_	_
5-7	503-506	can	_	_	_	_
5-8	507-519	successfully	_	_	_	_
5-9	520-527	provide	_	_	_	_
5-10	528-539	symptomatic	abstract[29]	new[29]	coref	13-26[78_29]
5-11	540-547	benefit	abstract[29]	new[29]	_	_
5-12	548-550	to	_	_	_	_
5-13	551-559	patients	person[30]	new[30]	coref	15-10[0_30]
5-14	560-564	with	person[30]	new[30]	_	_
5-15	565-575	metastatic	person[30]|abstract[31]	new[30]|giv[31]	coref	11-8[0_31]
5-16	576-583	sarcoma	person[30]|abstract[31]	new[30]|giv[31]	_	_
5-17	584-585	.	_	_	_	_

#Text=This study is limited by being retrospective such that the assessment of symptomatic improvement could only be assessed from documentation in medical records .
6-1	586-590	This	event[32]	giv[32]	coref	9-4[54_32]
6-2	591-596	study	event[32]	giv[32]	_	_
6-3	597-599	is	_	_	_	_
6-4	600-607	limited	_	_	_	_
6-5	608-610	by	_	_	_	_
6-6	611-616	being	_	_	_	_
6-7	617-630	retrospective	_	_	_	_
6-8	631-635	such	_	_	_	_
6-9	636-640	that	_	_	_	_
6-10	641-644	the	abstract[33]	new[33]	_	_
6-11	645-655	assessment	abstract[33]	new[33]	_	_
6-12	656-658	of	abstract[33]	new[33]	_	_
6-13	659-670	symptomatic	abstract[33]|abstract[34]	new[33]|new[34]	coref	7-11[40_34]
6-14	671-682	improvement	abstract[33]|abstract[34]	new[33]|new[34]	_	_
6-15	683-688	could	_	_	_	_
6-16	689-693	only	_	_	_	_
6-17	694-696	be	_	_	_	_
6-18	697-705	assessed	_	_	_	_
6-19	706-710	from	_	_	_	_
6-20	711-724	documentation	abstract[35]	new[35]	_	_
6-21	725-727	in	abstract[35]	new[35]	_	_
6-22	728-735	medical	abstract[35]|abstract[36]	new[35]|new[36]	_	_
6-23	736-743	records	abstract[35]|abstract[36]	new[35]|new[36]	_	_
6-24	744-745	.	_	_	_	_

#Text=It was therefore not possible to quantify the amount of symptomatic improvement seen or indeed to be certain of the accuracy of the results .
7-1	746-748	It	abstract	new	cata	7-1[0_38]
7-2	749-752	was	_	_	_	_
7-3	753-762	therefore	_	_	_	_
7-4	763-766	not	_	_	_	_
7-5	767-775	possible	_	_	_	_
7-6	776-778	to	abstract[38]	new[38]	_	_
7-7	779-787	quantify	abstract[38]	new[38]	_	_
7-8	788-791	the	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-9	792-798	amount	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-10	799-801	of	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-11	802-813	symptomatic	abstract[38]|abstract[39]|abstract[40]	new[38]|new[39]|giv[40]	coref	16-30[102_40]
7-12	814-825	improvement	abstract[38]|abstract[39]|abstract[40]	new[38]|new[39]|giv[40]	_	_
7-13	826-830	seen	_	_	_	_
7-14	831-833	or	_	_	_	_
7-15	834-840	indeed	_	_	_	_
7-16	841-843	to	_	_	_	_
7-17	844-846	be	_	_	_	_
7-18	847-854	certain	_	_	_	_
7-19	855-857	of	_	_	_	_
7-20	858-861	the	abstract[41]	new[41]	_	_
7-21	862-870	accuracy	abstract[41]	new[41]	_	_
7-22	871-873	of	abstract[41]	new[41]	_	_
7-23	874-877	the	abstract[41]|abstract[42]	new[41]|giv[42]	coref	18-1[113_42]
7-24	878-885	results	abstract[41]|abstract[42]	new[41]|giv[42]	_	_
7-25	886-887	.	_	_	_	_

#Text=The aim of this review , however , was to confirm that radiotherapy does have a role in the palliation of advanced sarcomas and to guide future prospective studies to gain more accurate evidence of the use of palliative radiotherapy in this setting .
8-1	888-891	The	abstract[43]	new[43]	_	_
8-2	892-895	aim	abstract[43]	new[43]	_	_
8-3	896-898	of	abstract[43]	new[43]	_	_
8-4	899-903	this	abstract[43]|abstract[44]	new[43]|new[44]	_	_
8-5	904-910	review	abstract[43]|abstract[44]	new[43]|new[44]	_	_
8-6	911-912	,	_	_	_	_
8-7	913-920	however	_	_	_	_
8-8	921-922	,	_	_	_	_
8-9	923-926	was	_	_	_	_
8-10	927-929	to	_	_	_	_
8-11	930-937	confirm	_	_	_	_
8-12	938-942	that	_	_	_	_
8-13	943-955	radiotherapy	abstract	giv	coref	8-39[52_0]
8-14	956-960	does	_	_	_	_
8-15	961-965	have	_	_	_	_
8-16	966-967	a	abstract[46]	giv[46]	_	_
8-17	968-972	role	abstract[46]	giv[46]	_	_
8-18	973-975	in	abstract[46]	giv[46]	_	_
8-19	976-979	the	abstract[46]|abstract[47]	giv[46]|giv[47]	coref	25-13[148_47]
8-20	980-990	palliation	abstract[46]|abstract[47]	giv[46]|giv[47]	_	_
8-21	991-993	of	abstract[46]|abstract[47]	giv[46]|giv[47]	_	_
8-22	994-1002	advanced	abstract[46]|abstract[47]|abstract[48]	giv[46]|giv[47]|new[48]	coref	10-5[58_48]
8-23	1003-1011	sarcomas	abstract[46]|abstract[47]|abstract[48]	giv[46]|giv[47]|new[48]	_	_
8-24	1012-1015	and	_	_	_	_
8-25	1016-1018	to	_	_	_	_
8-26	1019-1024	guide	_	_	_	_
8-27	1025-1031	future	abstract[49]	new[49]	_	_
8-28	1032-1043	prospective	abstract[49]	new[49]	_	_
8-29	1044-1051	studies	abstract[49]	new[49]	_	_
8-30	1052-1054	to	_	_	_	_
8-31	1055-1059	gain	_	_	_	_
8-32	1060-1064	more	abstract[50]	new[50]	coref	25-3[145_50]
8-33	1065-1073	accurate	abstract[50]	new[50]	_	_
8-34	1074-1082	evidence	abstract[50]	new[50]	_	_
8-35	1083-1085	of	abstract[50]	new[50]	_	_
8-36	1086-1089	the	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-37	1090-1093	use	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-38	1094-1096	of	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-39	1097-1107	palliative	abstract[50]|abstract[51]|abstract[52]	new[50]|new[51]|giv[52]	coref	12-10[69_52]
8-40	1108-1120	radiotherapy	abstract[50]|abstract[51]|abstract[52]	new[50]|new[51]|giv[52]	_	_
8-41	1121-1123	in	abstract[50]|abstract[51]|abstract[52]	new[50]|new[51]|giv[52]	_	_
8-42	1124-1128	this	abstract[50]|abstract[51]|abstract[52]|abstract[53]	new[50]|new[51]|giv[52]|new[53]	_	_
8-43	1129-1136	setting	abstract[50]|abstract[51]|abstract[52]|abstract[53]	new[50]|new[51]|giv[52]|new[53]	_	_
8-44	1137-1138	.	_	_	_	_

#Text=In addition , this study was limited by the heterogeneous population studied .
9-1	1139-1141	In	_	_	_	_
9-2	1142-1150	addition	_	_	_	_
9-3	1151-1152	,	_	_	_	_
9-4	1153-1157	this	event[54]	giv[54]	coref	16-1[94_54]
9-5	1158-1163	study	event[54]	giv[54]	_	_
9-6	1164-1167	was	_	_	_	_
9-7	1168-1175	limited	_	_	_	_
9-8	1176-1178	by	_	_	_	_
9-9	1179-1182	the	person[55]	new[55]	_	_
9-10	1183-1196	heterogeneous	person[55]	new[55]	_	_
9-11	1197-1207	population	person[55]	new[55]	_	_
9-12	1208-1215	studied	_	_	_	_
9-13	1216-1217	.	_	_	_	_

#Text=Both soft tissue and bone sarcomas of multiple types were included .
10-1	1218-1222	Both	object[56]	giv[56]	_	_
10-2	1223-1227	soft	object[56]	giv[56]	_	_
10-3	1228-1234	tissue	object[56]	giv[56]	_	_
10-4	1235-1238	and	_	_	_	_
10-5	1239-1243	bone	object|abstract[58]	giv|giv[58]	coref|coref|coref|coref	13-8|17-2[0_58]|13-8|17-2[0_58]
10-6	1244-1252	sarcomas	abstract[58]	giv[58]	_	_
10-7	1253-1255	of	abstract[58]	giv[58]	_	_
10-8	1256-1264	multiple	abstract[58]|abstract[59]	giv[58]|new[59]	coref	12-13[71_59]
10-9	1265-1270	types	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
10-10	1271-1275	were	_	_	_	_
10-11	1276-1284	included	_	_	_	_
10-12	1285-1286	.	_	_	_	_

#Text=The radiobiology of the different subtypes of sarcoma has not been well studied , but it is accepted that these tumours tend to be relatively radio-resistant , with a high alpha beta ratio .
11-1	1287-1290	The	abstract[60]	new[60]	ana	11-16[0_60]
11-2	1291-1303	radiobiology	abstract[60]	new[60]	_	_
11-3	1304-1306	of	abstract[60]	new[60]	_	_
11-4	1307-1310	the	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-5	1311-1320	different	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-6	1321-1329	subtypes	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-7	1330-1332	of	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-8	1333-1340	sarcoma	abstract[60]|abstract[61]|abstract	new[60]|new[61]|giv	coref	16-8[96_0]
11-9	1341-1344	has	_	_	_	_
11-10	1345-1348	not	_	_	_	_
11-11	1349-1353	been	_	_	_	_
11-12	1354-1358	well	_	_	_	_
11-13	1359-1366	studied	_	_	_	_
11-14	1367-1368	,	_	_	_	_
11-15	1369-1372	but	_	_	_	_
11-16	1373-1375	it	abstract	giv	_	_
11-17	1376-1378	is	_	_	_	_
11-18	1379-1387	accepted	_	_	_	_
11-19	1388-1392	that	_	_	_	_
11-20	1393-1398	these	abstract[64]	new[64]	coref	27-18[166_64]
11-21	1399-1406	tumours	abstract[64]	new[64]	_	_
11-22	1407-1411	tend	_	_	_	_
11-23	1412-1414	to	_	_	_	_
11-24	1415-1417	be	_	_	_	_
11-25	1418-1428	relatively	_	_	_	_
11-26	1429-1444	radio-resistant	_	_	_	_
11-27	1445-1446	,	_	_	_	_
11-28	1447-1451	with	_	_	_	_
11-29	1452-1453	a	quantity[66]	new[66]	_	_
11-30	1454-1458	high	quantity[66]	new[66]	_	_
11-31	1459-1464	alpha	quantity[66]	new[66]	_	_
11-32	1465-1469	beta	abstract|quantity[66]	new|new[66]	_	_
11-33	1470-1475	ratio	quantity[66]	new[66]	_	_
11-34	1476-1477	.	_	_	_	_

#Text=There have been several publications considering the role of palliative radiotherapy for other , more common solid tumour types .
12-1	1478-1483	There	_	_	_	_
12-2	1484-1488	have	_	_	_	_
12-3	1489-1493	been	_	_	_	_
12-4	1494-1501	several	abstract[67]	new[67]	_	_
12-5	1502-1514	publications	abstract[67]	new[67]	_	_
12-6	1515-1526	considering	_	_	_	_
12-7	1527-1530	the	abstract[68]	new[68]	_	_
12-8	1531-1535	role	abstract[68]	new[68]	_	_
12-9	1536-1538	of	abstract[68]	new[68]	_	_
12-10	1539-1549	palliative	abstract[68]|abstract[69]	new[68]|giv[69]	coref	13-35[0_69]
12-11	1550-1562	radiotherapy	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
12-12	1563-1566	for	abstract[68]	new[68]	_	_
12-13	1567-1572	other	abstract[68]|abstract[71]	new[68]|giv[71]	_	_
12-14	1573-1574	,	abstract[68]|abstract[71]	new[68]|giv[71]	_	_
12-15	1575-1579	more	abstract[68]|abstract[71]	new[68]|giv[71]	_	_
12-16	1580-1586	common	abstract[68]|abstract[71]	new[68]|giv[71]	_	_
12-17	1587-1592	solid	abstract[68]|abstract[71]	new[68]|giv[71]	_	_
12-18	1593-1599	tumour	abstract[68]|abstract|abstract[71]	new[68]|new|giv[71]	coref	13-16
12-19	1600-1605	types	abstract[68]|abstract[71]	new[68]|giv[71]	_	_
12-20	1606-1607	.	_	_	_	_

#Text=A meta-analysis has shown that when treating bone metastases from a number of different primary tumour sites and histology ’s , there appears to be little short-term symptomatic benefit in a fractionated course of radiotherapy , compared to a single fraction .
13-1	1608-1609	A	abstract[72]	new[72]	_	_
13-2	1610-1623	meta-analysis	abstract[72]	new[72]	_	_
13-3	1624-1627	has	_	_	_	_
13-4	1628-1633	shown	_	_	_	_
13-5	1634-1638	that	_	_	_	_
13-6	1639-1643	when	_	_	_	_
13-7	1644-1652	treating	_	_	_	_
13-8	1653-1657	bone	object|abstract[74]	giv|new[74]	coref|coref|coref|coref	14-16|14-16[87_74]|14-16|14-16[87_74]
13-9	1658-1668	metastases	abstract[74]	new[74]	_	_
13-10	1669-1673	from	_	_	_	_
13-11	1674-1675	a	place[76]	new[76]	_	_
13-12	1676-1682	number	place[76]	new[76]	_	_
13-13	1683-1685	of	place[76]	new[76]	_	_
13-14	1686-1695	different	place[76]	new[76]	_	_
13-15	1696-1703	primary	place[76]	new[76]	_	_
13-16	1704-1710	tumour	abstract|place[76]	giv|new[76]	_	_
13-17	1711-1716	sites	place[76]	new[76]	_	_
13-18	1717-1720	and	_	_	_	_
13-19	1721-1730	histology	abstract[77]	new[77]	_	_
13-20	1731-1733	’s	abstract[77]	new[77]	_	_
13-21	1734-1735	,	_	_	_	_
13-22	1736-1741	there	_	_	_	_
13-23	1742-1749	appears	_	_	_	_
13-24	1750-1752	to	_	_	_	_
13-25	1753-1755	be	_	_	_	_
13-26	1756-1762	little	abstract[78]	giv[78]	coref	17-27[112_78]
13-27	1763-1773	short-term	abstract[78]	giv[78]	_	_
13-28	1774-1785	symptomatic	abstract[78]	giv[78]	_	_
13-29	1786-1793	benefit	abstract[78]	giv[78]	_	_
13-30	1794-1796	in	abstract[78]	giv[78]	_	_
13-31	1797-1798	a	abstract[78]|abstract[79]	giv[78]|new[79]	_	_
13-32	1799-1811	fractionated	abstract[78]|abstract[79]	giv[78]|new[79]	_	_
13-33	1812-1818	course	abstract[78]|abstract[79]	giv[78]|new[79]	_	_
13-34	1819-1821	of	abstract[78]|abstract[79]	giv[78]|new[79]	_	_
13-35	1822-1834	radiotherapy	abstract[78]|abstract[79]|abstract	giv[78]|new[79]|giv	coref	15-17[91_0]
13-36	1835-1836	,	_	_	_	_
13-37	1837-1845	compared	_	_	_	_
13-38	1846-1848	to	_	_	_	_
13-39	1849-1850	a	quantity[81]	new[81]	coref	14-8[84_81]
13-40	1851-1857	single	quantity[81]	new[81]	_	_
13-41	1858-1866	fraction	quantity[81]	new[81]	_	_
13-42	1867-1868	.	_	_	_	_

#Text=Most oncologists therefore advocate the use of a single fraction to control pain secondary to bone metastases .
14-1	1869-1873	Most	person[82]	new[82]	_	_
14-2	1874-1885	oncologists	person[82]	new[82]	_	_
14-3	1886-1895	therefore	_	_	_	_
14-4	1896-1904	advocate	_	_	_	_
14-5	1905-1908	the	abstract[83]	new[83]	_	_
14-6	1909-1912	use	abstract[83]	new[83]	_	_
14-7	1913-1915	of	abstract[83]	new[83]	_	_
14-8	1916-1917	a	abstract[83]|quantity[84]	new[83]|giv[84]	coref	15-28[93_84]
14-9	1918-1924	single	abstract[83]|quantity[84]	new[83]|giv[84]	_	_
14-10	1925-1933	fraction	abstract[83]|quantity[84]	new[83]|giv[84]	_	_
14-11	1934-1936	to	_	_	_	_
14-12	1937-1944	control	_	_	_	_
14-13	1945-1949	pain	abstract	new	coref	29-38
14-14	1950-1959	secondary	_	_	_	_
14-15	1960-1962	to	_	_	_	_
14-16	1963-1967	bone	object|abstract[87]	giv|giv[87]	_	_
14-17	1968-1978	metastases	abstract[87]	giv[87]	_	_
14-18	1979-1980	.	_	_	_	_

#Text=With longer follow-up , however , it seems that patients treated with a fractionated course of palliative radiotherapy are less likely to need retreatment than those given a single fraction .
15-1	1981-1985	With	_	_	_	_
15-2	1986-1992	longer	time[88]	new[88]	_	_
15-3	1993-2002	follow-up	time[88]	new[88]	_	_
15-4	2003-2004	,	_	_	_	_
15-5	2005-2012	however	_	_	_	_
15-6	2013-2014	,	_	_	_	_
15-7	2015-2017	it	_	_	_	_
15-8	2018-2023	seems	_	_	_	_
15-9	2024-2028	that	_	_	_	_
15-10	2029-2037	patients	person	giv	coref	16-5[95_0]
15-11	2038-2045	treated	_	_	_	_
15-12	2046-2050	with	_	_	_	_
15-13	2051-2052	a	abstract[90]	new[90]	_	_
15-14	2053-2065	fractionated	abstract[90]	new[90]	_	_
15-15	2066-2072	course	abstract[90]	new[90]	_	_
15-16	2073-2075	of	abstract[90]	new[90]	_	_
15-17	2076-2086	palliative	abstract[90]|abstract[91]	new[90]|giv[91]	coref	16-13[97_91]
15-18	2087-2099	radiotherapy	abstract[90]|abstract[91]	new[90]|giv[91]	_	_
15-19	2100-2103	are	_	_	_	_
15-20	2104-2108	less	_	_	_	_
15-21	2109-2115	likely	_	_	_	_
15-22	2116-2118	to	_	_	_	_
15-23	2119-2123	need	_	_	_	_
15-24	2124-2135	retreatment	event	new	coref	28-52
15-25	2136-2140	than	_	_	_	_
15-26	2141-2146	those	_	_	_	_
15-27	2147-2152	given	_	_	_	_
15-28	2153-2154	a	quantity[93]	giv[93]	coref	17-15[110_93]
15-29	2155-2161	single	quantity[93]	giv[93]	_	_
15-30	2162-2170	fraction	quantity[93]	giv[93]	_	_
15-31	2171-2172	.	_	_	_	_

#Text=This study demonstrates that selected patients with advanced sarcoma can benefit from palliative radiotherapy provided their prognosis is long enough for the benefits from radiotherapy , in terms of symptomatic improvement , to outweigh the inconvenience of undergoing radiotherapy and the associated side effects that they may suffer .
16-1	2173-2177	This	event[94]	giv[94]	ana	17-10[0_94]
16-2	2178-2183	study	event[94]	giv[94]	_	_
16-3	2184-2196	demonstrates	_	_	_	_
16-4	2197-2201	that	_	_	_	_
16-5	2202-2210	selected	person[95]	giv[95]	ana	16-16[0_95]
16-6	2211-2219	patients	person[95]	giv[95]	_	_
16-7	2220-2224	with	person[95]	giv[95]	_	_
16-8	2225-2233	advanced	person[95]|abstract[96]	giv[95]|giv[96]	coref	25-15[0_96]
16-9	2234-2241	sarcoma	person[95]|abstract[96]	giv[95]|giv[96]	_	_
16-10	2242-2245	can	_	_	_	_
16-11	2246-2253	benefit	abstract	new	coref|none	16-22[100_0]|16-11[0_100]
16-12	2254-2258	from	_	_	_	_
16-13	2259-2269	palliative	abstract[97]	giv[97]	coref	16-25[0_97]
16-14	2270-2282	radiotherapy	abstract[97]	giv[97]	_	_
16-15	2283-2291	provided	_	_	_	_
16-16	2292-2297	their	person|abstract[99]	giv|new[99]	ana|coref|ana|coref	16-46|28-36[0_99]|16-46|28-36[0_99]
16-17	2298-2307	prognosis	abstract[99]	new[99]	_	_
16-18	2308-2310	is	_	_	_	_
16-19	2311-2315	long	_	_	_	_
16-20	2316-2322	enough	_	_	_	_
16-21	2323-2326	for	_	_	_	_
16-22	2327-2330	the	abstract[100]	new[100]	_	_
16-23	2331-2339	benefits	abstract[100]	new[100]	_	_
16-24	2340-2344	from	abstract[100]	new[100]	_	_
16-25	2345-2357	radiotherapy	abstract[100]|abstract	new[100]|giv	coref	16-38[104_0]
16-26	2358-2359	,	_	_	_	_
16-27	2360-2362	in	_	_	_	_
16-28	2363-2368	terms	_	_	_	_
16-29	2369-2371	of	_	_	_	_
16-30	2372-2383	symptomatic	abstract[102]	giv[102]	_	_
16-31	2384-2395	improvement	abstract[102]	giv[102]	_	_
16-32	2396-2397	,	_	_	_	_
16-33	2398-2400	to	_	_	_	_
16-34	2401-2409	outweigh	_	_	_	_
16-35	2410-2413	the	abstract[103]	new[103]	_	_
16-36	2414-2427	inconvenience	abstract[103]	new[103]	_	_
16-37	2428-2430	of	abstract[103]	new[103]	_	_
16-38	2431-2441	undergoing	abstract[103]|abstract[104]	new[103]|giv[104]	coref	17-19[111_104]
16-39	2442-2454	radiotherapy	abstract[103]|abstract[104]	new[103]|giv[104]	_	_
16-40	2455-2458	and	abstract[103]	new[103]	_	_
16-41	2459-2462	the	abstract[103]|abstract[106]	new[103]|new[106]	_	_
16-42	2463-2473	associated	abstract[103]|abstract[106]	new[103]|new[106]	_	_
16-43	2474-2478	side	abstract[103]|abstract|abstract[106]	new[103]|new|new[106]	_	_
16-44	2479-2486	effects	abstract[103]|abstract[106]	new[103]|new[106]	_	_
16-45	2487-2491	that	_	_	_	_
16-46	2492-2496	they	person	giv	coref	24-9
16-47	2497-2500	may	_	_	_	_
16-48	2501-2507	suffer	_	_	_	_
16-49	2508-2509	.	_	_	_	_

#Text=As sarcomas are felt to be intrinsically radio-resistant , it can be hypothesized that a single fraction of palliative radiotherapy may not be sufficient to offer adequate symptomatic benefit .
17-1	2510-2512	As	_	_	_	_
17-2	2513-2521	sarcomas	abstract	giv	_	_
17-3	2522-2525	are	_	_	_	_
17-4	2526-2530	felt	_	_	_	_
17-5	2531-2533	to	_	_	_	_
17-6	2534-2536	be	_	_	_	_
17-7	2537-2550	intrinsically	_	_	_	_
17-8	2551-2566	radio-resistant	_	_	_	_
17-9	2567-2568	,	_	_	_	_
17-10	2569-2571	it	event	giv	_	_
17-11	2572-2575	can	_	_	_	_
17-12	2576-2578	be	_	_	_	_
17-13	2579-2591	hypothesized	_	_	_	_
17-14	2592-2596	that	_	_	_	_
17-15	2597-2598	a	quantity[110]	giv[110]	coref	27-2[162_110]
17-16	2599-2605	single	quantity[110]	giv[110]	_	_
17-17	2606-2614	fraction	quantity[110]	giv[110]	_	_
17-18	2615-2617	of	quantity[110]	giv[110]	_	_
17-19	2618-2628	palliative	quantity[110]|abstract[111]	giv[110]|giv[111]	coref	21-21[129_111]
17-20	2629-2641	radiotherapy	quantity[110]|abstract[111]	giv[110]|giv[111]	_	_
17-21	2642-2645	may	_	_	_	_
17-22	2646-2649	not	_	_	_	_
17-23	2650-2652	be	_	_	_	_
17-24	2653-2663	sufficient	_	_	_	_
17-25	2664-2666	to	_	_	_	_
17-26	2667-2672	offer	_	_	_	_
17-27	2673-2681	adequate	abstract[112]	giv[112]	coref	28-16[176_112]
17-28	2682-2693	symptomatic	abstract[112]	giv[112]	_	_
17-29	2694-2701	benefit	abstract[112]	giv[112]	_	_
17-30	2702-2703	.	_	_	_	_

#Text=The results presented here suggest a higher symptomatic response rate with a biological effective dose ( BED ) of 50 or greater .
18-1	2704-2707	The	abstract[113]	giv[113]	_	_
18-2	2708-2715	results	abstract[113]	giv[113]	_	_
18-3	2716-2725	presented	_	_	_	_
18-4	2726-2730	here	_	_	_	_
18-5	2731-2738	suggest	_	_	_	_
18-6	2739-2740	a	abstract[115]	new[115]	coref	20-6[123_115]
18-7	2741-2747	higher	abstract[115]	new[115]	_	_
18-8	2748-2759	symptomatic	abstract[115]	new[115]	_	_
18-9	2760-2768	response	event|abstract[115]	new|new[115]	coref	20-6
18-10	2769-2773	rate	abstract[115]	new[115]	_	_
18-11	2774-2778	with	abstract[115]	new[115]	_	_
18-12	2779-2780	a	abstract[115]|quantity[116]	new[115]|new[116]	coref	26-2[0_116]
18-13	2781-2791	biological	abstract[115]|quantity[116]	new[115]|new[116]	_	_
18-14	2792-2801	effective	abstract[115]|quantity[116]	new[115]|new[116]	_	_
18-15	2802-2806	dose	abstract[115]|quantity[116]	new[115]|new[116]	_	_
18-16	2807-2808	(	_	_	_	_
18-17	2809-2812	BED	object	new	coref	20-10
18-18	2813-2814	)	_	_	_	_
18-19	2815-2817	of	_	_	_	_
18-20	2818-2820	50	quantity	new	_	_
18-21	2821-2823	or	_	_	_	_
18-22	2824-2831	greater	_	_	_	_
18-23	2832-2833	.	_	_	_	_

#Text=Figure 3
19-1	2834-2840	Figure	abstract[119]	new[119]	coref	23-1[133_119]
19-2	2841-2842	3	abstract[119]	new[119]	_	_

#Text=b demonstrates an increase in response rate with increasing BED up to 50 Gy4 .
20-1	2843-2844	b	abstract	new	coref	24-1
20-2	2845-2857	demonstrates	_	_	_	_
20-3	2858-2860	an	abstract[121]	new[121]	_	_
20-4	2861-2869	increase	abstract[121]	new[121]	_	_
20-5	2870-2872	in	abstract[121]	new[121]	_	_
20-6	2873-2881	response	abstract[121]|event|abstract[123]	new[121]|giv|giv[123]	coref|coref	21-4[127_0]|21-4[127_0]
20-7	2882-2886	rate	abstract[121]|abstract[123]	new[121]|giv[123]	_	_
20-8	2887-2891	with	_	_	_	_
20-9	2892-2902	increasing	_	_	_	_
20-10	2903-2906	BED	object	giv	coref	24-11[138_0]
20-11	2907-2909	up	_	_	_	_
20-12	2910-2912	to	_	_	_	_
20-13	2913-2915	50	quantity[125]	new[125]	coref	27-33[171_125]
20-14	2916-2919	Gy4	quantity[125]	new[125]	_	_
20-15	2920-2921	.	_	_	_	_

#Text=Beyond this point the response is maintained but does not appear to increase further , suggesting very high doses of palliative radiotherapy may not be necessary to achieve a good symptomatic response in this patient group .
21-1	2922-2928	Beyond	_	_	_	_
21-2	2929-2933	this	event[126]	new[126]	_	_
21-3	2934-2939	point	event[126]	new[126]	_	_
21-4	2940-2943	the	event[127]	giv[127]	coref	21-29[130_127]
21-5	2944-2952	response	event[127]	giv[127]	_	_
21-6	2953-2955	is	_	_	_	_
21-7	2956-2966	maintained	_	_	_	_
21-8	2967-2970	but	_	_	_	_
21-9	2971-2975	does	_	_	_	_
21-10	2976-2979	not	_	_	_	_
21-11	2980-2986	appear	_	_	_	_
21-12	2987-2989	to	_	_	_	_
21-13	2990-2998	increase	_	_	_	_
21-14	2999-3006	further	_	_	_	_
21-15	3007-3008	,	_	_	_	_
21-16	3009-3019	suggesting	_	_	_	_
21-17	3020-3024	very	quantity[128]	new[128]	_	_
21-18	3025-3029	high	quantity[128]	new[128]	_	_
21-19	3030-3035	doses	quantity[128]	new[128]	_	_
21-20	3036-3038	of	quantity[128]	new[128]	_	_
21-21	3039-3049	palliative	quantity[128]|abstract[129]	new[128]|giv[129]	coref	25-11[0_129]
21-22	3050-3062	radiotherapy	quantity[128]|abstract[129]	new[128]|giv[129]	_	_
21-23	3063-3066	may	_	_	_	_
21-24	3067-3070	not	_	_	_	_
21-25	3071-3073	be	_	_	_	_
21-26	3074-3083	necessary	_	_	_	_
21-27	3084-3086	to	_	_	_	_
21-28	3087-3094	achieve	_	_	_	_
21-29	3095-3096	a	event[130]	giv[130]	_	_
21-30	3097-3101	good	event[130]	giv[130]	_	_
21-31	3102-3113	symptomatic	event[130]	giv[130]	_	_
21-32	3114-3122	response	event[130]	giv[130]	_	_
21-33	3123-3125	in	event[130]	giv[130]	_	_
21-34	3126-3130	this	event[130]|person[131]	giv[130]|new[131]	coref	24-32[144_131]
21-35	3131-3138	patient	event[130]|person[131]	giv[130]|new[131]	_	_
21-36	3139-3144	group	event[130]|person[131]	giv[130]|new[131]	_	_
21-37	3145-3146	.	_	_	_	_

#Text=The one apparent outlier in
22-1	3147-3150	The	abstract[132]	new[132]	coref	24-23[142_132]
22-2	3151-3154	one	abstract[132]	new[132]	_	_
22-3	3155-3163	apparent	abstract[132]	new[132]	_	_
22-4	3164-3171	outlier	abstract[132]	new[132]	_	_
22-5	3172-3174	in	abstract[132]	new[132]	_	_

#Text=Figure 3
23-1	3175-3181	Figure	abstract[133]	giv[133]	_	_
23-2	3182-3183	3	abstract[133]	giv[133]	_	_

#Text=b is the 100 % symptomatic response in patients receiving a BED of 30 – 39.9 , this is likely to be an outlier as there was only one patient in this group .
24-1	3184-3185	b	abstract	giv	coref	24-3[136_0]
24-2	3186-3188	is	_	_	_	_
24-3	3189-3192	the	abstract[136]	giv[136]	ana	24-18[0_136]
24-4	3193-3196	100	quantity[135]|abstract[136]	new[135]|giv[136]	_	_
24-5	3197-3198	%	quantity[135]|abstract[136]	new[135]|giv[136]	_	_
24-6	3199-3210	symptomatic	abstract[136]	giv[136]	_	_
24-7	3211-3219	response	abstract[136]	giv[136]	_	_
24-8	3220-3222	in	abstract[136]	giv[136]	_	_
24-9	3223-3231	patients	abstract[136]|person	giv[136]|giv	coref	28-29[179_0]
24-10	3232-3241	receiving	_	_	_	_
24-11	3242-3243	a	object[138]	giv[138]	_	_
24-12	3244-3247	BED	object[138]	giv[138]	_	_
24-13	3248-3250	of	object[138]	giv[138]	_	_
24-14	3251-3253	30	object[138]|time[139]	giv[138]|new[139]	_	_
24-15	3254-3255	–	object[138]|time[139]	giv[138]|new[139]	_	_
24-16	3256-3260	39.9	object[138]|time[139]|quantity	giv[138]|new[139]|new	_	_
24-17	3261-3262	,	_	_	_	_
24-18	3263-3267	this	abstract	giv	_	_
24-19	3268-3270	is	_	_	_	_
24-20	3271-3277	likely	_	_	_	_
24-21	3278-3280	to	_	_	_	_
24-22	3281-3283	be	_	_	_	_
24-23	3284-3286	an	abstract[142]	giv[142]	_	_
24-24	3287-3294	outlier	abstract[142]	giv[142]	_	_
24-25	3295-3297	as	_	_	_	_
24-26	3298-3303	there	_	_	_	_
24-27	3304-3307	was	_	_	_	_
24-28	3308-3312	only	person[143]	giv[143]	_	_
24-29	3313-3316	one	person[143]	giv[143]	_	_
24-30	3317-3324	patient	person[143]	giv[143]	_	_
24-31	3325-3327	in	person[143]	giv[143]	_	_
24-32	3328-3332	this	person[143]|person[144]	giv[143]|giv[144]	_	_
24-33	3333-3338	group	person[143]|person[144]	giv[143]|giv[144]	_	_
24-34	3339-3340	.	_	_	_	_

#Text=Because of the limited evidence available in the use of radiotherapy for palliation in sarcoma the Royal College of Radiologists
25-1	3341-3348	Because	_	_	_	_
25-2	3349-3351	of	_	_	_	_
25-3	3352-3355	the	abstract[145]	giv[145]	_	_
25-4	3356-3363	limited	abstract[145]	giv[145]	_	_
25-5	3364-3372	evidence	abstract[145]	giv[145]	_	_
25-6	3373-3382	available	abstract[145]	giv[145]	_	_
25-7	3383-3385	in	_	_	_	_
25-8	3386-3389	the	abstract[146]	new[146]	_	_
25-9	3390-3393	use	abstract[146]	new[146]	_	_
25-10	3394-3396	of	abstract[146]	new[146]	_	_
25-11	3397-3409	radiotherapy	abstract[146]|abstract	new[146]|giv	coref	26-1
25-12	3410-3413	for	abstract[146]	new[146]	_	_
25-13	3414-3424	palliation	abstract[146]|abstract[148]	new[146]|giv[148]	_	_
25-14	3425-3427	in	abstract[146]|abstract[148]	new[146]|giv[148]	_	_
25-15	3428-3435	sarcoma	abstract[146]|abstract[148]|abstract	new[146]|giv[148]|giv	coref	29-14
25-16	3436-3439	the	abstract[146]|abstract[148]|organization[150]	new[146]|giv[148]|new[150]	coref	34-43[238_150]
25-17	3440-3445	Royal	abstract[146]|abstract[148]|organization[150]	new[146]|giv[148]|new[150]	_	_
25-18	3446-3453	College	abstract[146]|abstract[148]|organization[150]	new[146]|giv[148]|new[150]	_	_
25-19	3454-3456	of	abstract[146]|abstract[148]|organization[150]	new[146]|giv[148]|new[150]	_	_
25-20	3457-3469	Radiologists	abstract[146]|abstract[148]|organization[150]|person	new[146]|giv[148]|new[150]|new	coref	34-47

#Text=Radiotherapy dose fractionation guidance ( 3rd edition ) recommends several different dose fractionation schedules ( Table 5 ) .
26-1	3470-3482	Radiotherapy	animal|abstract[155]	giv|new[155]	appos|coref|appos|coref	26-6[156_155]|28-12|26-6[156_155]|28-12
26-2	3483-3487	dose	quantity|abstract[155]	giv|new[155]	coref	26-12
26-3	3488-3501	fractionation	object|abstract[155]	new|new[155]	coref	26-13
26-4	3502-3510	guidance	abstract[155]	new[155]	_	_
26-5	3511-3512	(	_	_	_	_
26-6	3513-3516	3rd	abstract[156]	giv[156]	_	_
26-7	3517-3524	edition	abstract[156]	giv[156]	_	_
26-8	3525-3526	)	_	_	_	_
26-9	3527-3537	recommends	_	_	_	_
26-10	3538-3545	several	abstract[159]	new[159]	coref	27-16[165_159]
26-11	3546-3555	different	abstract[159]	new[159]	_	_
26-12	3556-3560	dose	quantity|abstract[159]	giv|new[159]	coref	27-25
26-13	3561-3574	fractionation	object|abstract[159]	giv|new[159]	coref	27-26
26-14	3575-3584	schedules	abstract[159]	new[159]	_	_
26-15	3585-3586	(	_	_	_	_
26-16	3587-3592	Table	object[160]	new[160]	_	_
26-17	3593-3594	5	object[160]	new[160]	_	_
26-18	3595-3596	)	_	_	_	_
26-19	3597-3598	.	_	_	_	_

#Text=Excluding 8 Gy single fraction and 20 Gy in 5 fractions which are commonly used schedules for all solid tumours ; the remaining recommended dose fractionation schedules all have a BED of greater than 50 Gy4 .
27-1	3599-3608	Excluding	_	_	_	_
27-2	3609-3610	8	quantity[161]|quantity[162]	new[161]|giv[162]	_	_
27-3	3611-3613	Gy	quantity[161]|quantity[162]	new[161]|giv[162]	_	_
27-4	3614-3620	single	quantity[162]	giv[162]	_	_
27-5	3621-3629	fraction	quantity[162]	giv[162]	_	_
27-6	3630-3633	and	_	_	_	_
27-7	3634-3636	20	quantity[163]	new[163]	_	_
27-8	3637-3639	Gy	quantity[163]	new[163]	_	_
27-9	3640-3642	in	_	_	_	_
27-10	3643-3644	5	quantity[164]	new[164]	_	_
27-11	3645-3654	fractions	quantity[164]	new[164]	_	_
27-12	3655-3660	which	_	_	_	_
27-13	3661-3664	are	_	_	_	_
27-14	3665-3673	commonly	_	_	_	_
27-15	3674-3678	used	_	_	_	_
27-16	3679-3688	schedules	abstract[165]	giv[165]	coref	27-22[169_165]
27-17	3689-3692	for	abstract[165]	giv[165]	_	_
27-18	3693-3696	all	abstract[165]|abstract[166]	giv[165]|giv[166]	_	_
27-19	3697-3702	solid	abstract[165]|abstract[166]	giv[165]|giv[166]	_	_
27-20	3703-3710	tumours	abstract[165]|abstract[166]	giv[165]|giv[166]	_	_
27-21	3711-3712	;	_	_	_	_
27-22	3713-3716	the	abstract[169]	giv[169]	coref	34-12[227_169]
27-23	3717-3726	remaining	abstract[169]	giv[169]	_	_
27-24	3727-3738	recommended	abstract[169]	giv[169]	_	_
27-25	3739-3743	dose	quantity|abstract[169]	giv|giv[169]	coref	30-16[204_0]
27-26	3744-3757	fractionation	abstract|abstract[169]	giv|giv[169]	coref	33-32
27-27	3758-3767	schedules	abstract[169]	giv[169]	_	_
27-28	3768-3771	all	_	_	_	_
27-29	3772-3776	have	_	_	_	_
27-30	3777-3778	a	abstract[170]	new[170]	_	_
27-31	3779-3782	BED	abstract[170]	new[170]	_	_
27-32	3783-3785	of	abstract[170]	new[170]	_	_
27-33	3786-3793	greater	abstract[170]|quantity[171]	new[170]|giv[171]	_	_
27-34	3794-3798	than	abstract[170]|quantity[171]	new[170]|giv[171]	_	_
27-35	3799-3801	50	abstract[170]|quantity[171]	new[170]|giv[171]	_	_
27-36	3802-3805	Gy4	abstract[170]|quantity[171]	new[170]|giv[171]	_	_
27-37	3806-3807	.	_	_	_	_

#Text=Although this case series has demonstrated that very high doses of radiotherapy may not provide additional short-term symptomatic benefit , longer courses of radiotherapy may be considered in patients with a good performance status and prognosis in an attempt to provide a longer period of symptomatic benefit without the need for retreatment .
28-1	3808-3816	Although	_	_	_	_
28-2	3817-3821	this	abstract[173]	new[173]	coref	29-1[189_173]
28-3	3822-3826	case	person|abstract[173]	new|new[173]	coref	29-4
28-4	3827-3833	series	abstract[173]	new[173]	_	_
28-5	3834-3837	has	_	_	_	_
28-6	3838-3850	demonstrated	_	_	_	_
28-7	3851-3855	that	_	_	_	_
28-8	3856-3860	very	abstract[174]	new[174]	_	_
28-9	3861-3865	high	abstract[174]	new[174]	_	_
28-10	3866-3871	doses	abstract[174]	new[174]	_	_
28-11	3872-3874	of	abstract[174]	new[174]	_	_
28-12	3875-3887	radiotherapy	abstract[174]|abstract	new[174]|giv	coref	28-24
28-13	3888-3891	may	_	_	_	_
28-14	3892-3895	not	_	_	_	_
28-15	3896-3903	provide	_	_	_	_
28-16	3904-3914	additional	abstract[176]	giv[176]	coref	28-46[185_176]
28-17	3915-3925	short-term	abstract[176]	giv[176]	_	_
28-18	3926-3937	symptomatic	abstract[176]	giv[176]	_	_
28-19	3938-3945	benefit	abstract[176]	giv[176]	_	_
28-20	3946-3947	,	_	_	_	_
28-21	3948-3954	longer	place[177]	new[177]	coref	30-19[205_177]
28-22	3955-3962	courses	place[177]	new[177]	_	_
28-23	3963-3965	of	place[177]	new[177]	_	_
28-24	3966-3978	radiotherapy	place[177]|abstract	new[177]|giv	coref	29-11[191_0]
28-25	3979-3982	may	_	_	_	_
28-26	3983-3985	be	_	_	_	_
28-27	3986-3996	considered	_	_	_	_
28-28	3997-3999	in	_	_	_	_
28-29	4000-4008	patients	person[179]	giv[179]	coref	29-7[190_179]
28-30	4009-4013	with	person[179]	giv[179]	_	_
28-31	4014-4015	a	person[179]|abstract[181]	giv[179]|new[181]	_	_
28-32	4016-4020	good	person[179]|abstract[181]	giv[179]|new[181]	_	_
28-33	4021-4032	performance	person[179]|abstract|abstract[181]	giv[179]|new|new[181]	_	_
28-34	4033-4039	status	person[179]|abstract[181]	giv[179]|new[181]	_	_
28-35	4040-4043	and	person[179]	giv[179]	_	_
28-36	4044-4053	prognosis	person[179]|abstract	giv[179]|giv	_	_
28-37	4054-4056	in	_	_	_	_
28-38	4057-4059	an	abstract[183]	new[183]	_	_
28-39	4060-4067	attempt	abstract[183]	new[183]	_	_
28-40	4068-4070	to	_	_	_	_
28-41	4071-4078	provide	_	_	_	_
28-42	4079-4080	a	abstract[184]	new[184]	_	_
28-43	4081-4087	longer	abstract[184]	new[184]	_	_
28-44	4088-4094	period	abstract[184]	new[184]	_	_
28-45	4095-4097	of	abstract[184]	new[184]	_	_
28-46	4098-4109	symptomatic	abstract[184]|abstract[185]	new[184]|giv[185]	_	_
28-47	4110-4117	benefit	abstract[184]|abstract[185]	new[184]|giv[185]	_	_
28-48	4118-4125	without	_	_	_	_
28-49	4126-4129	the	abstract[186]	new[186]	_	_
28-50	4130-4134	need	abstract[186]	new[186]	_	_
28-51	4135-4138	for	abstract[186]	new[186]	_	_
28-52	4139-4150	retreatment	abstract[186]|event	new[186]|giv	_	_
28-53	4151-4152	.	_	_	_	_

#Text=A previously published case series of 17 patients who received palliative radiotherapy for sarcoma using 39 Gy in 13 fractions over two and a half weeks demonstrated this was well tolerated and provided high rates of durable pain control .
29-1	4153-4154	A	abstract[189]	giv[189]	_	_
29-2	4155-4165	previously	abstract[189]	giv[189]	_	_
29-3	4166-4175	published	abstract[189]	giv[189]	_	_
29-4	4176-4180	case	person|abstract[189]	giv|giv[189]	_	_
29-5	4181-4187	series	abstract[189]	giv[189]	_	_
29-6	4188-4190	of	abstract[189]	giv[189]	_	_
29-7	4191-4193	17	abstract[189]|person[190]	giv[189]|giv[190]	coref	30-10[203_190]
29-8	4194-4202	patients	abstract[189]|person[190]	giv[189]|giv[190]	_	_
29-9	4203-4206	who	_	_	_	_
29-10	4207-4215	received	_	_	_	_
29-11	4216-4226	palliative	abstract[191]	giv[191]	coref	30-22[0_191]
29-12	4227-4239	radiotherapy	abstract[191]	giv[191]	_	_
29-13	4240-4243	for	_	_	_	_
29-14	4244-4251	sarcoma	abstract	giv	ana	29-28
29-15	4252-4257	using	_	_	_	_
29-16	4258-4260	39	quantity[193]	new[193]	_	_
29-17	4261-4263	Gy	quantity[193]	new[193]	_	_
29-18	4264-4266	in	quantity[193]	new[193]	_	_
29-19	4267-4269	13	quantity[193]|quantity[194]	new[193]|new[194]	_	_
29-20	4270-4279	fractions	quantity[193]|quantity[194]	new[193]|new[194]	_	_
29-21	4280-4284	over	quantity[193]|quantity[194]	new[193]|new[194]	_	_
29-22	4285-4288	two	quantity[193]|quantity[194]	new[193]|new[194]	_	_
29-23	4289-4292	and	_	_	_	_
29-24	4293-4294	a	time[195]	new[195]	_	_
29-25	4295-4299	half	time[195]	new[195]	_	_
29-26	4300-4305	weeks	time[195]	new[195]	_	_
29-27	4306-4318	demonstrated	_	_	_	_
29-28	4319-4323	this	abstract	giv	coref	34-16
29-29	4324-4327	was	_	_	_	_
29-30	4328-4332	well	_	_	_	_
29-31	4333-4342	tolerated	_	_	_	_
29-32	4343-4346	and	_	_	_	_
29-33	4347-4355	provided	_	_	_	_
29-34	4356-4360	high	abstract[197]	new[197]	_	_
29-35	4361-4366	rates	abstract[197]	new[197]	_	_
29-36	4367-4369	of	abstract[197]	new[197]	_	_
29-37	4370-4377	durable	abstract[197]|abstract[199]	new[197]|new[199]	_	_
29-38	4378-4382	pain	abstract[197]|abstract|abstract[199]	new[197]|giv|new[199]	_	_
29-39	4383-4390	control	abstract[197]|abstract[199]	new[197]|new[199]	_	_
29-40	4391-4392	.	_	_	_	_

#Text=Collection of survival data may help to assess if the correct patients are being offered higher dose , longer courses of radiotherapy .
30-1	4393-4403	Collection	abstract[200]	new[200]	_	_
30-2	4404-4406	of	abstract[200]	new[200]	_	_
30-3	4407-4415	survival	abstract[200]|event|abstract[202]	new[200]|new|new[202]	coref|coref	32-17[211_0]|32-17[211_0]
30-4	4416-4420	data	abstract[200]|abstract[202]	new[200]|new[202]	_	_
30-5	4421-4424	may	_	_	_	_
30-6	4425-4429	help	_	_	_	_
30-7	4430-4432	to	_	_	_	_
30-8	4433-4439	assess	_	_	_	_
30-9	4440-4442	if	_	_	_	_
30-10	4443-4446	the	person[203]	giv[203]	coref	33-26[0_203]
30-11	4447-4454	correct	person[203]	giv[203]	_	_
30-12	4455-4463	patients	person[203]	giv[203]	_	_
30-13	4464-4467	are	_	_	_	_
30-14	4468-4473	being	_	_	_	_
30-15	4474-4481	offered	_	_	_	_
30-16	4482-4488	higher	quantity[204]	giv[204]	coref	33-29[219_204]
30-17	4489-4493	dose	quantity[204]	giv[204]	_	_
30-18	4494-4495	,	_	_	_	_
30-19	4496-4502	longer	place[205]	giv[205]	_	_
30-20	4503-4510	courses	place[205]	giv[205]	_	_
30-21	4511-4513	of	place[205]	giv[205]	_	_
30-22	4514-4526	radiotherapy	place[205]|abstract	giv[205]|giv	coref	32-13[210_0]
30-23	4527-4528	.	_	_	_	_

#Text=Figure 4
31-1	4529-4535	Figure	abstract[207]	new[207]	_	_
31-2	4536-4537	4	abstract[207]	new[207]	_	_

#Text=however does not appear to show any correlation between the BED of the radiotherapy delivered and overall survival .
32-1	4538-4545	however	_	_	_	_
32-2	4546-4550	does	_	_	_	_
32-3	4551-4554	not	_	_	_	_
32-4	4555-4561	appear	_	_	_	_
32-5	4562-4564	to	_	_	_	_
32-6	4565-4569	show	_	_	_	_
32-7	4570-4573	any	abstract[208]	new[208]	_	_
32-8	4574-4585	correlation	abstract[208]	new[208]	_	_
32-9	4586-4593	between	abstract[208]	new[208]	_	_
32-10	4594-4597	the	abstract[208]|abstract[209]	new[208]|new[209]	_	_
32-11	4598-4601	BED	abstract[208]|abstract[209]	new[208]|new[209]	_	_
32-12	4602-4604	of	abstract[208]|abstract[209]	new[208]|new[209]	_	_
32-13	4605-4608	the	abstract[208]|abstract[209]|abstract[210]	new[208]|new[209]|giv[210]	_	_
32-14	4609-4621	radiotherapy	abstract[208]|abstract[209]|abstract[210]	new[208]|new[209]|giv[210]	_	_
32-15	4622-4631	delivered	_	_	_	_
32-16	4632-4635	and	_	_	_	_
32-17	4636-4643	overall	event[211]	giv[211]	_	_
32-18	4644-4652	survival	event[211]	giv[211]	_	_
32-19	4653-4654	.	_	_	_	_

#Text=Interpretation of this data is extremely limited because of the heterogeneity of the patient population with multiple different histological subtypes and the small numbers of patients treated with each dose and fractionation schedule .
33-1	4655-4669	Interpretation	abstract[212]	new[212]	_	_
33-2	4670-4672	of	abstract[212]	new[212]	_	_
33-3	4673-4677	this	abstract[212]|abstract[213]	new[212]|new[213]	coref	34-24[0_213]
33-4	4678-4682	data	abstract[212]|abstract[213]	new[212]|new[213]	_	_
33-5	4683-4685	is	_	_	_	_
33-6	4686-4695	extremely	_	_	_	_
33-7	4696-4703	limited	_	_	_	_
33-8	4704-4711	because	_	_	_	_
33-9	4712-4714	of	_	_	_	_
33-10	4715-4718	the	abstract[214]	new[214]	_	_
33-11	4719-4732	heterogeneity	abstract[214]	new[214]	_	_
33-12	4733-4735	of	abstract[214]	new[214]	_	_
33-13	4736-4739	the	abstract[214]|abstract[215]	new[214]|new[215]	_	_
33-14	4740-4747	patient	abstract[214]|abstract[215]	new[214]|new[215]	_	_
33-15	4748-4758	population	abstract[214]|abstract[215]	new[214]|new[215]	_	_
33-16	4759-4763	with	abstract[214]|abstract[215]	new[214]|new[215]	_	_
33-17	4764-4772	multiple	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	coref	34-15[229_216]
33-18	4773-4782	different	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
33-19	4783-4795	histological	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
33-20	4796-4804	subtypes	abstract[214]|abstract[215]|abstract[216]	new[214]|new[215]|new[216]	_	_
33-21	4805-4808	and	abstract[214]|abstract[215]	new[214]|new[215]	_	_
33-22	4809-4812	the	abstract[214]|abstract[215]|quantity[217]	new[214]|new[215]|new[217]	_	_
33-23	4813-4818	small	abstract[214]|abstract[215]|quantity[217]	new[214]|new[215]|new[217]	_	_
33-24	4819-4826	numbers	abstract[214]|abstract[215]|quantity[217]	new[214]|new[215]|new[217]	_	_
33-25	4827-4829	of	abstract[214]|abstract[215]|quantity[217]	new[214]|new[215]|new[217]	_	_
33-26	4830-4838	patients	abstract[214]|abstract[215]|quantity[217]|person	new[214]|new[215]|new[217]|giv	_	_
33-27	4839-4846	treated	_	_	_	_
33-28	4847-4851	with	_	_	_	_
33-29	4852-4856	each	quantity[219]|abstract[220]	giv[219]|new[220]	coref|coref|coref|coref	34-7[224_219]|34-7[225_220]|34-7[224_219]|34-7[225_220]
33-30	4857-4861	dose	quantity[219]|abstract[220]	giv[219]|new[220]	_	_
33-31	4862-4865	and	abstract[220]	new[220]	_	_
33-32	4866-4879	fractionation	abstract[220]|object|abstract[222]	new[220]|giv|new[222]	coref|coref	34-12|34-12
33-33	4880-4888	schedule	abstract[220]|abstract[222]	new[220]|new[222]	_	_
33-34	4889-4890	.	_	_	_	_

#Text=To gain a better understanding of the most appropriate dose and fractionation schedules for different sarcoma subtypes large volume , multicentre , prospective data collections is required using a small number of different dose and fractionation schedules , ideally those outlined by the Royal College of Radiologists ( Table 5 ) .
34-1	4891-4893	To	_	_	_	_
34-2	4894-4898	gain	_	_	_	_
34-3	4899-4900	a	abstract[223]	new[223]	_	_
34-4	4901-4907	better	abstract[223]	new[223]	_	_
34-5	4908-4921	understanding	abstract[223]	new[223]	_	_
34-6	4922-4924	of	abstract[223]	new[223]	_	_
34-7	4925-4928	the	abstract[223]|quantity[224]|abstract[225]	new[223]|giv[224]|giv[225]	_	_
34-8	4929-4933	most	abstract[223]|quantity[224]|abstract[225]	new[223]|giv[224]|giv[225]	_	_
34-9	4934-4945	appropriate	abstract[223]|quantity[224]|abstract[225]	new[223]|giv[224]|giv[225]	_	_
34-10	4946-4950	dose	abstract[223]|quantity[224]|abstract[225]	new[223]|giv[224]|giv[225]	_	_
34-11	4951-4954	and	abstract[223]|abstract[225]	new[223]|giv[225]	_	_
34-12	4955-4968	fractionation	abstract[223]|abstract[225]|object|abstract[227]	new[223]|giv[225]|giv|giv[227]	coref|coref|coref|coref	34-36|34-36[237_227]|34-36|34-36[237_227]
34-13	4969-4978	schedules	abstract[223]|abstract[225]|abstract[227]	new[223]|giv[225]|giv[227]	_	_
34-14	4979-4982	for	abstract[223]|abstract[225]|abstract[227]	new[223]|giv[225]|giv[227]	_	_
34-15	4983-4992	different	abstract[223]|abstract[225]|abstract[227]|abstract[229]	new[223]|giv[225]|giv[227]|giv[229]	_	_
34-16	4993-5000	sarcoma	abstract[223]|abstract[225]|abstract[227]|abstract|abstract[229]	new[223]|giv[225]|giv[227]|giv|giv[229]	_	_
34-17	5001-5009	subtypes	abstract[223]|abstract[225]|abstract[227]|abstract[229]	new[223]|giv[225]|giv[227]|giv[229]	_	_
34-18	5010-5015	large	abstract[223]|abstract[225]|abstract[227]|abstract[229]|abstract[230]	new[223]|giv[225]|giv[227]|giv[229]|new[230]	_	_
34-19	5016-5022	volume	abstract[223]|abstract[225]|abstract[227]|abstract[229]|abstract[230]	new[223]|giv[225]|giv[227]|giv[229]|new[230]	_	_
34-20	5023-5024	,	abstract[223]|abstract[225]|abstract[227]|abstract[229]	new[223]|giv[225]|giv[227]|giv[229]	_	_
34-21	5025-5036	multicentre	abstract[223]|abstract[225]|abstract[227]|abstract[229]|place	new[223]|giv[225]|giv[227]|giv[229]|new	_	_
34-22	5037-5038	,	_	_	_	_
34-23	5039-5050	prospective	abstract[233]	new[233]	_	_
34-24	5051-5055	data	abstract|abstract[233]	giv|new[233]	_	_
34-25	5056-5067	collections	abstract[233]	new[233]	_	_
34-26	5068-5070	is	_	_	_	_
34-27	5071-5079	required	_	_	_	_
34-28	5080-5085	using	_	_	_	_
34-29	5086-5087	a	abstract[234]	new[234]	_	_
34-30	5088-5093	small	abstract[234]	new[234]	_	_
34-31	5094-5100	number	abstract[234]	new[234]	_	_
34-32	5101-5103	of	abstract[234]	new[234]	_	_
34-33	5104-5113	different	abstract[234]|quantity[235]	new[234]|new[235]	_	_
34-34	5114-5118	dose	abstract[234]|quantity[235]	new[234]|new[235]	_	_
34-35	5119-5122	and	abstract[234]	new[234]	_	_
34-36	5123-5136	fractionation	abstract[234]|object|abstract[237]	new[234]|giv|giv[237]	_	_
34-37	5137-5146	schedules	abstract[234]|abstract[237]	new[234]|giv[237]	_	_
34-38	5147-5148	,	_	_	_	_
34-39	5149-5156	ideally	_	_	_	_
34-40	5157-5162	those	_	_	_	_
34-41	5163-5171	outlined	_	_	_	_
34-42	5172-5174	by	_	_	_	_
34-43	5175-5178	the	organization[238]	giv[238]	_	_
34-44	5179-5184	Royal	organization[238]	giv[238]	_	_
34-45	5185-5192	College	organization[238]	giv[238]	_	_
34-46	5193-5195	of	organization[238]	giv[238]	_	_
34-47	5196-5208	Radiologists	organization[238]|person	giv[238]|giv	_	_
34-48	5209-5210	(	_	_	_	_
34-49	5211-5216	Table	_	_	_	_
34-50	5217-5218	5	_	_	_	_
34-51	5219-5220	)	_	_	_	_
34-52	5221-5222	.	_	_	_	_
